查看购物车
  • Traditional Chinese
  • English
2021-2031年北美抗生素和抗真菌药物市场报告：范围、细分、动态和竞争分析
市场调查报告书
商品编码
1871447

2021-2031年北美抗生素和抗真菌药物市场报告：范围、细分、动态和竞争分析

North America Antibiotics & Antimycotics Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 183 Pages | 订单完成后即时交付

价格

预计北美抗生素和抗真菌药物市场将大幅成长，到 2031 年将达到约 247.2659 亿美元，高于 2023 年的 164.3434 亿美元，预测期内年复合成长率(CAGR) 为 5.2%。

执行摘要和市场分析

北美抗生素和抗真菌药物市场的成长主要受以下因素驱动：传染病日益流行、人们对抗菌素抗药性的认识不断提高以及持续的药物创新。主要产业参与者正投资研发新的製剂和联合疗法以应对这些挑战。此外，强有力的监管支持和先进的医疗保健体係也促进了市场的扩张。儘管面临抗药性和严格的审批流程等挑战，但对有效抗菌治疗的需求依然强劲，尤其是在医院环境和免疫功能低下患者群体中。

市场区隔分析

北美抗生素和抗真菌药物市场可根据药物类别、适应症、给药途径和配销通路进行细分：

  • 药物类别：市场涵盖多种药物类别，例如青霉素、头孢菌素、碳青霉烯类、大环内酯类、氨基糖苷类、喹诺酮类、磺胺类、四环素类、唑类等。 2023年，青霉素占据最大的市场份额。
  • 适应症：市场分为皮肤感染、呼吸道感染、泌尿道感染 (UTI)、败血症、耳部感染、胃肠道感染和其他感染，其中皮肤感染在 2023 年占据市场份额领先。
  • 给药途径：包括口服、外用和其他方法，口服给药在 2023 年占据市场主导地位。
  • 配销通路：市场分为医院药房、零售药房和线上药房，其中医院药房在 2023 年占据最大份额。

市场展望

人们对真菌感染及其严重健康后果的认识不断提高，是推动抗生素和抗真菌药物市场成长的重要因素。全球真菌感染行动基金（GAFFI）在2023年报告称，全球有超过3亿人患有严重的真菌疾病，每年导致约150万人死亡，超过疟疾和结核病死亡人数的总和。这一令人担忧的趋势促使人们进行广泛的教育活动，并改善诊断能力，从而提高医护人员和患者对及时治疗必要性的认识。

分子检测等诊断方法的创新促进了真菌病原体的早期发现，进一步增加了对有效抗真菌治疗的需求。美国疾病管制与预防中心 (CDC) 已启动耳念珠菌监测项目，以提升实验室能力和疫情管理水准。此外，全球真菌感染与真菌学会 (GAFFI) 的十年消除真菌疾病路线图强调了有效诊断的必要条件。包括国际人类和动物真菌学会 (ISHAM) 和欧洲疾病预防控制中心 (ECDC) 在内的多个组织也在努力提高公众对真菌感染负担的认识，并改善预防、诊断和治疗策略。每年9月16日至20日举行的「真菌疾病宣传週」旨在提高公众对真菌疾病日益普遍以及采取适当应对措施必要性的认识。

国家概况

北美抗生素和抗真菌药物市场主要由美国、加拿大和墨西哥组成，其中美国在2023年占据最大的市场份额。美国市场的成长主要受真菌和细菌感染发病率上升以及对有效治疗方案的需求所推动。肺炎是一种常见的呼吸道感染，每年在美国影响约150万成年人，导致大量住院和死亡病例。阿莫西林和阿奇霉素是门诊最常使用的抗生素之一。

药物研发的不断进步正在加速新型抗生素和抗真菌药物的开发，从而应对抗生素抗药性和创新疗法的需求。抗菌药物管理计画的推行，促使人们更加谨慎地使用抗生素，尤其是在医院感染高发生率的环境中。

关键参与者

北美抗生素和抗真菌药物市场的主要公司包括辉瑞公司、诺华公司、赛诺菲公司、罗氏公司、默克公司、葛兰素史克公司、强生公司、西普拉公司、拜耳公司、艾伯维公司和安斯泰来製药公司。这些公司正在推行产品上市、审批和合作等策略，以增强其市场份额并为消费者提供创新解决方案。

目录

第一章：引言

第二章：执行概要

  • 关键见解

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基数：
    • 数据三角测量：
    • 国家层面资料：

第四章：北美抗生素和抗真菌药物市场概况

  • 概述
  • PEST分析

第五章：北美抗生素和抗真菌药物市场－主要市场动态

  • 市场驱动因素
    • 传染病发生率不断上升
    • 人们对真菌感染的认识不断提高
  • 市场限制
    • 抗菌素抗药性、经济障碍和繁琐的监管程序
  • 市场机会
    • 持续的资金投入与研发计划
  • 未来趋势
    • 产品开发和治疗输送方法的技术进步
  • 驾驶员和安全带的影响：

第六章：抗生素和抗真菌药物市场——北美分析

  • 2021-2031年北美抗生素和抗真菌药物市场收入
  • 北美抗生素和抗真菌药物市场预测分析

第七章：北美抗生素和抗真菌药物市场分析－按药物类别划分

  • 青霉素
  • 头孢菌素
  • 碳青霉烯类
  • 大环内酯类
  • 氨基糖苷类
  • 奎诺酮类
  • 磺胺类药物
  • 四环素类
  • 唑类
  • 其他的

第八章：北美抗生素和抗真菌药物市场分析－按适应症划分

  • 皮肤感染
  • 呼吸道感染
  • 泌尿道感染（UTI）
  • 败血症
  • 耳部感染
  • 胃肠道感染
  • 其他的

第九章：北美抗生素和抗真菌药物市场分析－依给药途径划分

  • 口服
  • 主题
  • 其他的

第十章：北美抗生素和抗真菌药物市场分析－按配销通路划分

  • 医院药房
  • 零售药局
  • 网路药局

第十一章：北美抗生素和抗真菌药物市场——国别分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第十二章：抗生素和抗真菌药物市场－产业概况

  • 概述
  • 抗生素和抗真菌药物市场成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十三章：公司简介

  • Pfizer Inc
  • Novartis AG
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • GSK Plc
  • Johnson & Johnson
  • Cipla Ltd
  • Bayer AG
  • AbbVie Inc
  • Astellas Pharma Inc

第十四章：附录

Product Code: BMIRE00032104

The North America antibiotics and antimycotics market is projected to grow significantly, reaching approximately USD 24,726.59 million by 2031, up from USD 16,434.34 million in 2023, reflecting a compound annual growth rate (CAGR) of 5.2% during the forecast period.

Executive Summary and Market Analysis

The growth of the North American antibiotics and antimycotics market is primarily driven by the increasing prevalence of infectious diseases, heightened awareness regarding antimicrobial resistance, and ongoing pharmaceutical innovations. Major industry players are investing in new formulations and combination therapies to address these challenges. Additionally, robust regulatory support and advanced healthcare systems contribute to the market's expansion. Despite facing hurdles such as drug resistance and stringent approval processes, the demand for effective antimicrobial treatments remains strong, especially in hospital environments and among immunocompromised patients.

Market Segmentation Analysis

The North America antibiotics and antimycotics market can be segmented based on drug class, indication, route of administration, and distribution channel:

  • Drug Class: The market includes various drug classes such as penicillin, cephalosporins, carbapenems, macrolides, aminoglycosides, quinolones, sulfonamides, tetracyclines, azoles, and others. In 2023, penicillin held the largest market share.
  • Indication: The market is segmented into skin infections, respiratory infections, urinary tract infections (UTI), septicemia, ear infections, gastrointestinal infections, and others, with skin infections leading in market share in 2023.
  • Route of Administration: This includes oral, topical, and other methods, with oral administration dominating the market in 2023.
  • Distribution Channel: The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, where hospital pharmacies accounted for the largest share in 2023.

Market Outlook

The increasing awareness of fungal infections and their serious health implications is a significant factor driving the growth of the antibiotics and antimycotics market. The Global Action Fund for Fungal Infections (GAFFI) reported in 2023 that over 300 million people globally suffer from severe fungal diseases, leading to approximately 1.5 million deaths annually, surpassing the combined fatalities from malaria and tuberculosis. This alarming trend has prompted extensive educational initiatives and improved diagnostic capabilities, enhancing awareness among healthcare providers and patients about the necessity for timely treatment.

Innovations in diagnostic methods, such as molecular testing, have facilitated the early detection of fungal pathogens, further increasing the demand for effective antifungal treatments. The Centers for Disease Control and Prevention (CDC) has initiated programs to monitor Candida auris, enhancing laboratory capabilities and outbreak management. Furthermore, GAFFI's 10-year roadmap for eliminating fungal diseases emphasizes the essential conditions for effective diagnostics. Various organizations, including the International Society for Human and Animal Mycology (ISHAM) and the European Centre for Disease Prevention and Control (ECDC), are also working to highlight the burden of fungal infections and improve prevention, diagnosis, and treatment strategies. The annual Fungal Disease Awareness Week, observed from September 16-20, aims to raise awareness about the growing prevalence of fungal diseases and the need for appropriate responses.

Country Insights

The North American antibiotics and antimycotics market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2023. The growth in the US market is fueled by the rising incidence of fungal and bacterial infections and the demand for effective treatment options. Pneumonia, a common respiratory infection, affects approximately 1.5 million adults annually in the US, leading to significant hospital admissions and fatalities. Amoxicillin and azithromycin are among the most frequently prescribed antibiotics in outpatient settings.

Ongoing advancements in pharmaceutical research are accelerating the development of new antibiotics and antifungal agents, addressing concerns about antibiotic resistance and the need for innovative therapies. The emphasis on antimicrobial stewardship programs is promoting a more judicious approach to antibiotic prescriptions, particularly in hospital settings where hospital-acquired infections are prevalent.

Key Players

Prominent companies in the North America antibiotics and antimycotics market include Pfizer Inc., Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc., GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc., and Astellas Pharma Inc. These companies are pursuing strategies such as product launches, approvals, and collaborations to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. North America Antibiotics and Antimycotics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Antibiotics and Antimycotics Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Prevalence of Infectious Diseases
    • 5.1.2 Growing Awareness About Fungal Infections
  • 5.2 Market Restraints
    • 5.2.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
  • 5.3 Market Opportunities
    • 5.3.1 Ongoing Funding and Research & Development Initiatives
  • 5.4 Future Trends
    • 5.4.1 Technological Advancements in Product Development and Treatment Delivery Approaches
  • 5.5 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - North America Analysis

  • 6.1 North America Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • 6.2 North America Antibiotics and Antimycotics Market Forecast Analysis

7. North America Antibiotics and Antimycotics Market Analysis - by Drug Class

  • 7.1 Penicillin
    • 7.1.1 Overview
    • 7.1.2 Penicillin: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.2 Cephalosporines
    • 7.2.1 Overview
    • 7.2.2 Cephalosporines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.3 Carbapenems
    • 7.3.1 Overview
    • 7.3.2 Carbapenems: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.4 Macrolides
    • 7.4.1 Overview
    • 7.4.2 Macrolides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.5 Aminoglycosides
    • 7.5.1 Overview
    • 7.5.2 Aminoglycosides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.6 Quinolones
    • 7.6.1 Overview
    • 7.6.2 Quinolones: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.7 Sulfonamides
    • 7.7.1 Overview
    • 7.7.2 Sulfonamides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.8 Tetracyclines
    • 7.8.1 Overview
    • 7.8.2 Tetracyclines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.9 Azoles
    • 7.9.1 Overview
    • 7.9.2 Azoles: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 7.10 Others
    • 7.10.1 Overview
    • 7.10.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. North America Antibiotics and Antimycotics Market Analysis - by Indication

  • 8.1 Skin Infections
    • 8.1.1 Overview
    • 8.1.2 Skin Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.2 Respiratory Infections
    • 8.2.1 Overview
    • 8.2.2 Respiratory Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.3 Urinary Tract Infections (UTI)
    • 8.3.1 Overview
    • 8.3.2 Urinary Tract Infections (UTI): North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.4 Septicemia
    • 8.4.1 Overview
    • 8.4.2 Septicemia: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.5 Ear Infections
    • 8.5.1 Overview
    • 8.5.2 Ear Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.6 Gastrointestinal Infections
    • 8.6.1 Overview
    • 8.6.2 Gastrointestinal Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. North America Antibiotics and Antimycotics Market Analysis - by Route Of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.2 Topical
    • 9.2.1 Overview
    • 9.2.2 Topical: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

10. North America Antibiotics and Antimycotics Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)

11. North America Antibiotics and Antimycotics Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Antibiotics and Antimycotics Market Overview
    • 11.1.2 North America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.1 North America Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
      • 11.1.2.2 United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 11.1.2.2.1 United States: North America Antibiotics and Antimycotics Market Share - by Drug Class
        • 11.1.2.2.2 United States: North America Antibiotics and Antimycotics Market Share - by Indication
        • 11.1.2.2.3 United States: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 11.1.2.2.4 United States: North America Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 11.1.2.3 Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 11.1.2.3.1 Canada: North America Antibiotics and Antimycotics Market Share - by Drug Class
        • 11.1.2.3.2 Canada: North America Antibiotics and Antimycotics Market Share - by Indication
        • 11.1.2.3.3 Canada: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 11.1.2.3.4 Canada: North America Antibiotics and Antimycotics Market Share - by Distribution Channel
      • 11.1.2.4 Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 11.1.2.4.1 Mexico: North America Antibiotics and Antimycotics Market Share - by Drug Class
        • 11.1.2.4.2 Mexico: North America Antibiotics and Antimycotics Market Share - by Indication
        • 11.1.2.4.3 Mexico: North America Antibiotics and Antimycotics Market Share - by Route Of Administration
        • 11.1.2.4.4 Mexico: North America Antibiotics and Antimycotics Market Share - by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Antibiotics and Antimycotics Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Pfizer Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Novartis AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sanofi SA
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 F. Hoffmann-La Roche Ltd
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Merck & Co Inc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 GSK Plc
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Johnson & Johnson
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Cipla Ltd
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Bayer AG
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 AbbVie Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments
  • 13.11 Astellas Pharma Inc
    • 13.11.1 Key Facts
    • 13.11.2 Business Description
    • 13.11.3 Products and Services
    • 13.11.4 Financial Overview
    • 13.11.5 SWOT Analysis
    • 13.11.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Antibiotics and Antimycotics Market Segmentation
  • Table 2. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Table 3. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Drug Class
  • Table 4. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Indication
  • Table 5. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Route Of Administration
  • Table 6. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Distribution Channel
  • Table 7. North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
  • Table 8. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 9. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 10. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 11. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 12. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 13. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 14. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 15. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 16. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
  • Table 17. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Indication
  • Table 18. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
  • Table 19. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
  • Table 20. Recent Organic Growth Strategies in Antibiotics and Antimycotics Market
  • Table 21. Recent Inorganic Growth Strategies in the Antibiotics and Antimycotics Market
  • Table 22. Glossary of Terms, Antibiotics and Antimycotics Market

List Of Figures

  • Figure 1. North America Antibiotics and Antimycotics Market Segmentation - Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Antibiotics and Antimycotics Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Antibiotics and Antimycotics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Penicillin: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 8. Cephalosporines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 9. Carbapenems: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 10. Macrolides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 11. Aminoglycosides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 12. Quinolones: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 13. Sulfonamides: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 14. Tetracyclines: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 15. Azoles: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 16. Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 17. North America Antibiotics and Antimycotics Market Share (%) - by Indication (2023 and 2031)
  • Figure 18. Skin Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 19. Respiratory Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 20. Urinary Tract Infections (UTI): North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 21. Septicemia: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Ear Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. Gastrointestinal Infections: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 25. North America Antibiotics and Antimycotics Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 26. Oral: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. Topical: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. Others: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 29. North America Antibiotics and Antimycotics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 30. Hospital Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Retail Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. Online Pharmacies: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 33. North America Antibiotics and Antimycotics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 34. United States: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 35. Canada: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 36. Mexico: North America Antibiotics and Antimycotics Market - Revenue and Forecast, 2021- 2031 (US$ Million)
  • Figure 37. Growth Strategies in Antibiotics and Antimycotics Market